Sunshine Biopharma Inc. (OTCBB: SBFM) is pleased to announce that it has recently received notification that the United States Patent and Trademark Office has issued a "Notice of Allowance" for the patent application covering its lead anti-tumor compound, Adva-27a. The allowed claims protect Adva-27a and extensively cover various formulations, derivatives and cancer applications.
Sunshine Biopharma's recently announced preclinical results showed that Adva-27a has an excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of cancer cells, particularly multidrug resistant Breast Cancer cells. Adva-27a is appears to be unique in its ability to destroy multidrug resistant cancer cells. Sunshine Biopharma is moving forward with the next steps in the development of Adva-27a which include GMP manufacturing, IND-enabling studies and Phase I clinical trials.
Novel antibodies show promise for tumor targeting and RAD51 inhibition